Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $11.5 million.

  • Cardiff Oncology's Accumulated Expenses rose 6082.23% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 6082.23%. This contributed to the annual value of $7.9 million for FY2024, which is 146.47% up from last year.
  • Latest data reveals that Cardiff Oncology reported Accumulated Expenses of $11.5 million as of Q3 2025, which was up 6082.23% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Accumulated Expenses registered a high of $11.5 million during Q3 2025, and its lowest value of $3.0 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $6.3 million, with a median of $6.1 million in 2022.
  • As far as peak fluctuations go, Cardiff Oncology's Accumulated Expenses skyrocketed by 7480.51% in 2022, and later crashed by 1239.05% in 2023.
  • Over the past 5 years, Cardiff Oncology's Accumulated Expenses (Quarter) stood at $4.5 million in 2021, then grew by 14.36% to $5.2 million in 2022, then skyrocketed by 50.34% to $7.8 million in 2023, then rose by 1.46% to $7.9 million in 2024, then surged by 46.12% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $9.9 million for Q2 2025, and $8.9 million during Q1 2025.